Transplantation for Peri-Hilar and Intrahepatic Cholangiocarcinoma With mTOR Immunosuppression
Transplantation Proceedings · 2025
DOI: 10.1016/j.transproceed.2025.02.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Samar Semaan und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Houston Methodist Hospital, Houston, TX. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Liver Transplantation, Bile Duct Neoplasms, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: American Society of Transplant Surgeons, Houston Methodist Academic Institute.
Abstract (Originalsprache)
BACKGROUND: Cholangiocarcinoma (CCA) has rising incidence and mortality rates. Outcomes from combination systemic, loco-regional therapy (LRT) and liver transplantation (LT) are improving, but more granular data are needed to inform evidence-based management, including patient selection and immunosuppression. METHODS: Patients with peri-hilar (PH) and intrahepatic (IH) CCA who underwent LT at a single center between January 2008 and February 2023 were reviewed retrospectively. Primary outcomes were overall survival (OS) and recurrence-free survival (RFS) with significance determined by Cox proportional hazards model. RESULTS: During the study period, 53 patients underwent LT for either PH (n = 27), or IH (26). Cohort had mean age 58.5 years old (IQR, 47.0-63.0), body mass index (BMI) 25.9 (IQR, 22.9-30.0) kg/m2, and mean biologic MELD 9 (IQR, 7-17). Most frequent etiology was PSC (n = 12, 22.6%). Forty-nine patients (92.5%) received neoadjuvant therapy, including systemic (n = 48, 90.6%) and locoregional therapy (LRT) (n = 22, 41.5%), to which PH tumors were both most and least responsive (P = .03). On explant pathology, tumor were a median size of 3.5 cm and lympho-vascular invasion (LVI) was present in 13 (24.5%) cases. Median follow-up post-transplant was 910 days (IQR, 407-1509). Probabilities of OS and RFS at 3-years post-LT were 69.2% (95% CI, 56.9%-84.2%) and 57.4% (95% CI, 43.7%-75.4%). In multivariable analysis, OS was associated with tumor type and LVI, and RFS with age, BMI, PSC and LRT. After a median post-LT period of 38 days (IQR, 27-79.5), 39 (71.7%) patients started mTOR inhibition with lowered tacrolimus goal. Cox proportional hazard model showed significant association of OS with mTOR inhibition, though this was not validated by a time-dependent co-variate approach. CONCLUSIONS: In this single center cohort of CCA, post-LT outcomes were significantly greater for patients with IH tumors and no LVI. Immunosuppression with mTOR inhibition was not consistently associated with outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Houston Methodist Hospital, Houston, TX.
- Department of Surgery, Houston Methodist Hospital, Houston, TX; Department of Surgery, Weill Cornell Medical College, New York, NY.
- Sherrie and Alan Conover Center for Liver Disease and Transplantation, Department of Medicine, Houston Methodist Hospital, Houston, TX; Department of Medicine, Weill Cornell Medical College, New York, NY.
- Sherrie and Alan Conover Center for Liver Disease and Transplantation, Department of Medicine, Houston Methodist Hospital, Houston, TX.
- Department of Surgery, Houston Methodist Hospital, Houston, TX; Department of Surgery, Weill Cornell Medical College, New York, NY; Sherrie and Alan Conover Center for Liver Disease and Transplantation, Department of Me…
- Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX.
Förderung
- American Society of Transplant Surgeons
- Houston Methodist Academic Institute
Zitieren
APA
Semaan, S., Connor, A. A., Saharia, A., Kodali, S., Elaileh, A., Patel, K., Soliman, N., Basra, T., Victor, D. W., Simon, C. J., Cheah, Y. L., Hobeika, M. J., Mobley, C. M., Dhingra, S., Schwartz, M. R., Maqsood, A., Heyne, K., Abdelrahim, M., Li, X. C., …, & Ghobrial, R. M. (2025). Transplantation for Peri-Hilar and Intrahepatic Cholangiocarcinoma With mTOR Immunosuppression. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2025.02.001
Vancouver
Semaan S, Connor AA, Saharia A, Kodali S, Elaileh A, Patel K, et al. Transplantation for Peri-Hilar and Intrahepatic Cholangiocarcinoma With mTOR Immunosuppression. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2025.02.001
BibTeX
@article{Semaan2025,
author = {Semaan, Samar and Connor, Ashton A and Saharia, Ashish and Kodali, Sudha and Elaileh, Ahmed and Patel, Khush and Soliman, Nadine and Basra, Tamneet and Victor, David W and Simon, Caroline J and Cheah, Yee Lee and Hobeika, Mark J and Mobley, Constance M and Dhingra, Sadhna and Schwartz, Mary R and Maqsood, Anaum and Heyne, Kirk and Abdelrahim, Maen and Li, Xian C and Javle, Milind and Vauthey, Jean-Nicolas and Gaber, A Osama and Ghobrial, R Mark},
title = {Transplantation for Peri-Hilar and Intrahepatic Cholangiocarcinoma With mTOR Immunosuppression},
journal = {Transplantation Proceedings},
year = {2025},
doi = {10.1016/j.transproceed.2025.02.001}
}
EUVIMED